SEC Form 4 · accession 0001140361-18-019611

BIOMARIN PHARMACEUTICAL INC · BMRN

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

Reporting owner

Officer — Chief Executive Officer · Director

Period of report

Apr 23, 2018

Accepted (ET)

Apr 25, 2018 · 8:30 pm EDT

Rule 10b5-1 plan

unknown — predates the checkbox

Issuer CIK

0001048477

Table I — non-derivative securities

Security	Date	Code	Shares	Price	A/D	Owned after	D/I	Nature of ownership
Common Stock^F1	Apr 23, 2018	M	10,000	$38.59	A	300,031	D
Common Stock^F1,F2	Apr 23, 2018	S	10,000	$82.5811	D	290,031	D
Common Stock^F1	Apr 24, 2018	M	10,000	$38.59	A	300,031	D
Common Stock^F1,F3	Apr 24, 2018	S	10,000	$82.2887	D	290,031	D
Common Stock	holding	—	—		—	182,201	I	Shares held by Jean-Jacques Bienaime Family Trust

Security	Conv. / exercise price	Date	Code	Shares	A/D	Exercisable	Expires	Underlying	Underlying shares	Owned after	D/I
Stock Option (Right to buy Common Stock)^F1,F4	$38.59	Apr 23, 2018	M	10,000	D	Nov 22, 2008	May 21, 2018	Common Stock	10,000	122,500	D
Stock Option (Right to buy Common Stock)^F1,F4	$38.59	Apr 24, 2018	M	10,000	D	Nov 22, 2008	May 21, 2018	Common Stock	10,000	112,500	D

F1Trade made pursuant to a 10b5-1 plan executed on November 14, 2017.
F2The price in column 4 is the weighted average price. The price actually received ranged from $82.20 to $82.95. The reporting person shall provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price.
F3The price in column 4 is the weighted average price. The price actually received ranged from $81.76 to $83.29. The reporting person shall provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price.
F4Reflects the number of options outstanding after the transactions from this specific stock option grant.